Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2460 | Personalized health education Wiki | 0.71 |
drug1377 | General health education Wiki | 0.71 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.
Description: Days alive and off mechanical ventilation at day 60. Measured only among patients who receive invasive mechanical ventilation.
Measure: Ventilator Free Days Time: Measured from hospital admission day 60 after admission.Description: Duration from hospital admission until cessation of supplemental oxygen use. Measured only among patients who do not receive invasive mechanical ventilation.
Measure: Duration of supplemental oxygen use Time: Measured from hospital admission to day 60.Description: Survival at day 60 or hospital discharge
Measure: All cause mortality Time: Measured at day 60 or at hospital discharge, whichever comes first.Description: Systemic inflammation at 5 days measured by serum IL-6.
Measure: Systemic inflammation Time: Measured at day 5 post enrollment.The purpose of this study is to explore the effectiveness of processed human amniotic fluid as a treatment for COVID-19.
Description: Assess reduction of inflammation in COVID-19 patients, potentially leading to a decrease in the need for critical care. This will be assessed by measurement of C-reactive protein levels before and after the intervention. Units: mg/dL
Measure: C-reactive protein Time: Baseline through post-treatment (6 days)Description: Comparison of mortality between intervention and control groups
Measure: Death within 30 Days Time: Baseline through 30 daysDescription: Comparison of days spend in ICU between intervention and control groups
Measure: ICU-free days at 30 days Time: Baseline through 30 daysDescription: Comparison of days spent in hospital between intervention and control groups
Measure: Hospital length of stay Time: From date of hospital admission through date of discharge or death, whichever comes first (up to 100 days)Description: Comparison of mechanical ventilation incidence between intervention and control groups
Measure: Need for invasive mechanical ventilation Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)Description: Comparison of mean biomarker level change between intervention and control groups. Units: pg/mL
Measure: Biomarker levels (interleukin-6) Time: Baseline through post-treatment (6 days)Description: Comparison of mean biomarker level change between intervention and control groups. Units: ug/mL
Measure: Biomarker levels (d-dimer) Time: Baseline through post-treatment (6 days)Description: Comparison of mean biomarker level change between intervention and control groups. Units: u/L
Measure: Biomarker levels (lactate dehydrogenase) Time: Baseline through post-treatment (6 days)Description: Comparison of ECMO incidence between intervention and control groups
Measure: Need for ECMO Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)Description: Compare frequency of major adverse cardiac events (MACE) between intervention and control groups
Measure: Major adverse cardiac events Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)Description: Comparison of PROMIS (Patient-Reported Outcomes Measurement Information System) questionnaire results on a computer-adaptive platform between intervention and control groups using T-scores. Scale mean = 50, standard deviation = 10.
Measure: Patient-reported functional status Time: Administered at 1, 3, 6, and 12 months post discharge (1 year)Description: Patients will be administered a 20-question self-report measure of PTSD symptoms. Total scores range from 0-80. Scores of 31-33 or above generally indicate clinically likely PTSD.
Measure: PTSD Checklist Time: Administered at 1, 3, 6, and 12 months post discharge (1 year)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports